{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:21:46Z","timestamp":1791685306446,"version":"4.3.4"},"reference-count":34,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100019944","name":"Sanofi Aventis Deutschland GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2019,7,2]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify real-world, age-related trends in the use of insulin glargine 100 U\/mL (Gla-100) as part of basal-supported oral therapy (BOT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>The prospective, observational Titration and Optimization registry enrolled patients with poorly controlled type 2 diabetes mellitus initiated on Gla-100 BOT. The primary outcome was the proportion of patients with capillary fasting blood glucose (FBG) \u2264110\u2009mg\/dL on \u22652 occasions and\/or who met their individual HbA1c target within 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2462 patients were analyzed (&lt;65 years: n=1122; 65\u201374 years: n=771; \u226575 years: n=569). Diabetes duration (6.8, 8.9, and 11.2 years, p&lt;0.0001) and proportion of women (40.7%, 47.9%, and 55.7%, p&lt;0.0001) increased with age. Baseline HbA1c was highest in &lt;65-year-olds (8.6% vs 8.4% and 8.5%, p&lt;0.0001). Gla-100 up-titration until 12 months was highest in &lt;65-year-olds (+11.6 U\/day), compared with 65\u201374 (+10.2 U\/day) and \u226575 years (+8.8; p&lt;0.0001) but similar by units per kilogram, as was the decrease in FBG (&lt;65: \u221264.1\u2009mg\/dL; 65\u201374: \u221256.1\u2009mg\/dL; \u226575: \u221253.4\u2009mg\/dL) and HbA1c (&lt;65: \u22121.47%; 65\u201374: \u22121.31%; \u226575: \u22121.22%, p&lt;0.0001). At 12 months, 65.9% of participants met the primary endpoint, with no significant difference between age groups. The proportion achieving their individual HbA1c target was lower for &lt;65-year-olds (46.0% vs 54.3% and 54.7%; p&lt;0.02). Symptomatic hypoglycemia incidence was more common in the \u226575-year-old group (3.4% vs 1.4% and 1.4%; p=0.0126).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BOT with Gla-100 results in similar improvements of glycemic values with low risk of hypoglycemia across age groups. Given the link between HbA1c and long-term cardiovascular risk, ensuring appropriately stringent target-setting, intensification of basal insulin and making sure hypoglycemia is avoided is of paramount importance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      Database:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/awbdb.bfarm.de\">https:\/\/awbdb.bfarm.de<\/jats:ext-link>\n                      ; Identifier: 1641; Date of registration: September 23, 2013\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2019-000668","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T06:47:57Z","timestamp":1564728477000},"page":"e000668","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U\/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs"],"prefix":"10.1136","volume":"7","author":[{"given":"Andreas","family":"Fritsche","sequence":"first","affiliation":[{"name":"Medizinische Klinik IV, Universit\u00e4t T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Anderten","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis Anderten-Krok & Partner, Hildesheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MD, PhD","given":"Martin","family":"Pfohl","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Evang. Krankenhaus Bethesda gGmbH, Duisburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pscherer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Sophien- undHufeland-Klinikum, Weimar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Borck","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Pegelow","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmakologie und Pr\u00e4ventive Medizin, Cloppenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Seufert","sequence":"additional","affiliation":[{"name":"Abteilung Endokrinologie und Diabetologie, Klinik f\u00fcr Innere Medizin II, Medizinische Fakult\u00e4t, Albert-Ludwig-Universit\u00e4t Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2025073112212854000_7.1.e000668.1","unstructured":"Sinclair A , Dunning T , Colagiuri S , et al . IDF global guideline for managing older people with type 2 diabetes. International Diabetes Federation, 2013. Available: www.idf.org"},{"key":"2025073112212854000_7.1.e000668.2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.exger.2013.02.017","article-title":"Age \u2265 60 years was an independent risk factor for diabetes-related complications despite good control of cardiovascular risk factors in patients with type 2 diabetes mellitus","volume":"48","author":"Chew","year":"2013","journal-title":"Exp Gerontol"},{"key":"2025073112212854000_7.1.e000668.3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005082-200201000-00003","article-title":"Risk factors for type 2 diabetes mellitus","volume":"16","author":"Fletcher","year":"2002","journal-title":"J Cardiovasc Nurs"},{"key":"2025073112212854000_7.1.e000668.4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jamainternmed.2013.12956","article-title":"Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study","volume":"174","author":"Huang","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2025073112212854000_7.1.e000668.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S014"},{"key":"2025073112212854000_7.1.e000668.6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/dme.12401","article-title":"Use of clinical targets in diabetes patient education: qualitative analysis of the expectations and impact of a structured self-management programme in type 1 diabetes","volume":"31","author":"Snow","year":"2014","journal-title":"Diabet Med"},{"key":"2025073112212854000_7.1.e000668.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht108"},{"key":"2025073112212854000_7.1.e000668.8","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S009"},{"key":"2025073112212854000_7.1.e000668.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7160.703"},{"key":"2025073112212854000_7.1.e000668.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2025073112212854000_7.1.e000668.11","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"2025073112212854000_7.1.e000668.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-015-0051-0","article-title":"Treatment intensification using long-acting insulin\u2014predictors of future basal insulin supported oral therapy in the dive registry","volume":"15","author":"Danne","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"2025073112212854000_7.1.e000668.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-008-0052-9"},{"key":"2025073112212854000_7.1.e000668.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-014-0698-4"},{"key":"2025073112212854000_7.1.e000668.15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/dom.13535","article-title":"Titration and optimization trial for the initiation of insulin glargine 100 U\/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs","volume":"21","author":"Seufert","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2025073112212854000_7.1.e000668.16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12282"},{"key":"2025073112212854000_7.1.e000668.17","first-page":"283","article-title":"Insulin therapy in the elderly with type 2 diabetes","volume":"40","author":"Eriksson","year":"2015","journal-title":"Minerva Endocrinol"},{"key":"2025073112212854000_7.1.e000668.18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40520-013-0125-7","article-title":"Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials","volume":"26","author":"Curtis","year":"2014","journal-title":"Aging Clin Exp Res"},{"key":"2025073112212854000_7.1.e000668.19","unstructured":"The World Bank Group . Life expectancy at birth. Germany: The World Bank Group, 2017."},{"key":"2025073112212854000_7.1.e000668.20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.32098\/mltj.04.2013.17","article-title":"Strength and muscle mass loss with aging process. Age and strength loss","volume":"3","author":"Keller","year":"2013","journal-title":"Muscles Ligaments Tendons J"},{"key":"2025073112212854000_7.1.e000668.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041358","article-title":"Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis","volume":"7","author":"Kadowaki","year":"2012","journal-title":"PLoS One"},{"key":"2025073112212854000_7.1.e000668.22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-016-0342-9","article-title":"Effects of age on glycemic control in patients with type 2 diabetes treated with insulin analysis of the PREDICTIVE\u2122 303 study","volume":"33","author":"Bhargava","year":"2016","journal-title":"Drugs Aging"},{"key":"2025073112212854000_7.1.e000668.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02341.x"},{"key":"2025073112212854000_7.1.e000668.24","first-page":"391","article-title":"Treating the elderly diabetic patient: special considerations","volume":"7","author":"Kezerle","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025073112212854000_7.1.e000668.25","first-page":"306","article-title":"Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus","volume":"18","author":"Zografou","year":"2014","journal-title":"Hippokratia"},{"key":"2025073112212854000_7.1.e000668.26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jgs.13388","article-title":"A real-world study of the effect of timing of insulin initiation on outcomes in older Medicare beneficiaries with type 2 diabetes mellitus","volume":"63","author":"Bhattacharya","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"2025073112212854000_7.1.e000668.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-12-200306170-00006"},{"key":"2025073112212854000_7.1.e000668.28","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.6.1282"},{"key":"2025073112212854000_7.1.e000668.29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.diabres.2016.10.003","article-title":"Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: a survey research","volume":"122","author":"Escalada","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073112212854000_7.1.e000668.30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jppr.1163","article-title":"Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention","volume":"45","author":"Jafari","year":"2015","journal-title":"J Pharm Pract Res"},{"key":"2025073112212854000_7.1.e000668.31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diabres.2015.10.026","article-title":"High rate of hypoglycemia in 6770 type 2 diabetes patients with comorbid dementia: a multicenter cohort study on 215,932 patients from the German\/Austrian diabetes registry","volume":"112","author":"Prinz","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073112212854000_7.1.e000668.32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jdiacomp.2015.05.016","article-title":"Risk factors associated with falls in elderly patients with type 2 diabetes","volume":"29","author":"Chiba","year":"2015","journal-title":"J Diabetes Complications"},{"key":"2025073112212854000_7.1.e000668.33","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0168"},{"key":"2025073112212854000_7.1.e000668.34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13300-016-0215-6","article-title":"Basal insulin persistence, associated factors, and outcomes after treatment initiation: a retrospective database study among people with type 2 diabetes mellitus in Japan","volume":"8","author":"Hadjiyianni","year":"2017","journal-title":"Diabetes Ther"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2019-000668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:21:40Z","timestamp":1753989700000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2019-000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bmjdrc-2019-000668"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2019-000668","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}